Teva Pharmaceutical Industries Limited
TEVA · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $17.3B | $16.5B | +4.3% |
| Operating income | $2.16B | −$303M | |
| Net income | $1.41B | −$1.64B |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 3, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $4.39B | $4.48B | −1.9% |
| Operating income | $714M | $882M | −19.0% |
| Net income | $233M | $433M | −46.2% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Teva's revenue in FY2025?
- $17.3B in FY2025 (Fiscal year ended Dec 31, 2025), +4.3% vs $16.5B a year earlier, per its 10-K filed Feb 2026.
- Was Teva profitable in FY2025?
- Yes: net income was $1.41B and operating income $2.16B in FY2025.
- What was Teva's revenue in Q3 2026?
- $4.39B (−1.9% vs a year earlier), per its Form 10-Q filed Nov 3, 2026.